Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

PILÁTOVÁ Kateřina BENCSIKOVÁ Beatrix DEMLOVÁ Regina VALÍK Dalibor ZDRAŽILOVÁ DUBSKÁ Lenka

Year of publication 2018
Type Article in Periodical
Magazine / Source Cancer Immunology and Immunotherapy
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.ncbi.nlm.nih.gov/pubmed/29748897
Doi http://dx.doi.org/10.1007/s00262-018-2166-4
Keywords myeloid-derived suppresor cells; granulocyty colony-stimulating factor; cancer; prophylaxis of febrile neutropenia; CITIM 2017
Attached files
Description Myeloid-derived suppressor cells (MDSCs) have been shown to contribute to tumor escape from host immune surveillance and to cancer progression by production of tumor-promoting soluble factors. Granulocyte colony-stimulating factor (G-CSF) is a principle cytokine controlling granulocyte number. Recombinant human G-CSF (rhG-CSF) has become the main therapeutic agent for the treatment of neutropenia and prophylaxis of febrile neutropenia in cancer patients. However, we show here that rhG-CSF triggers accumulation of granulocytic and monocytic subsets. Consequently, we discuss the pharmacological use of granulopoiesis stimulating factors not only in the context of febrile neutropenia but also from the perspective of MDSC-dependent and MDSC-independent mechanisms of immunosuppression and cancer angiogenesis.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.